Mechanisms underlying altered ubiquitin-proteasome system activity during heart failure and pharmacological

Xiaofei Gao1, Yu Cao2, Hangyan Li3

  • 1Department of Cardiology, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, 310006, Zhejiang, China.

Insights

The ubiquitin-proteasome system (UPS) is crucial for heart health. Dysregulation of this protein degradation pathway contributes to heart failure (HF), offering new therapeutic targets.

Area of Science:

  • Cardiovascular Science
  • Molecular Biology
  • Biochemistry

Background:

  • Heart failure (HF) is a growing global health concern with complex, incompletely understood causes.
  • Protein turnover is vital for cardiac homeostasis; impaired protein degradation systems are implicated in heart disease.
  • The ubiquitin-proteasome system (UPS) regulates cardiac cell structure and function through protein degradation.

Purpose of the Study:

  • To review the mechanisms of altered UPS activity in heart failure.
  • To outline UPS regulators influencing HF progression.
  • To discuss the therapeutic potential of small molecules targeting UPS in HF.

Main Methods:

  • Literature review focusing on the role of the UPS in cardiovascular physiology and pathophysiology.
  • Analysis of research on UPS dysregulation in the context of heart failure.
  • Synthesis of findings on UPS regulators and small molecule interventions.

Main Results:

  • The UPS plays a significant role in cardiac homeostasis and its dysregulation is linked to heart failure.
  • Several UPS components and regulators have been identified as key players in HF progression.
  • Novel therapeutic strategies targeting the UPS for HF treatment are emerging.

Conclusions:

  • Understanding UPS alterations in HF is essential for developing targeted therapies.
  • The UPS represents a promising target for pharmacological intervention in heart failure.
  • Small molecules offer potential for modulating UPS function to treat HF.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
329
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.4K
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
298
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
284
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
440
Pathophysiology of Cardiac Performance01:29

Pathophysiology of Cardiac Performance

Typical heart performance is influenced by heart rate, rhythm, myocardial contraction, and metabolism or blood flow. The cardiac muscle exhibits distinct electrophysiological features, including pacemaker activity and calcium channel control, which play a vital role in the heart's response to various drugs. The autonomic nervous system, comprising the sympathetic and parasympathetic branches, regulates heart rate. Sympathetic activation increases heart rate, while parasympathetic activation...
490